Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy.

The key pathogenesis of IgAN involves overproduction of galactose-deficient IgA1 (Gd-IgA1) and anti-Gd-IgA1 antibodies, resulting in formation of circulating immune complexes that deposit in the glomerular mesangium.

IgAN的关键病理机制涉及半乳糖缺乏的IgA1（Gd-IgA1）和抗Gd-IgA1抗体的过度产生，导致循环免疫复合物的形成并沉积在肾小球系膜。

Consequently, emerging therapeutic strategies for IgAN aim to target and reduce aberrant Gd-IgA1 and its associated immune complexes.

因此，针对IgAN的新兴治疗策略旨在靶向并减少异常的Gd-IgA1及其相关的免疫复合物。

This disease-modifying approach confers benefits across multiple stages of IgAN progression, particularly in the early phase to halt irreversible renal damage.

这种疾病修饰性方法在IgAN进展的多个阶段都带来了益处，特别是在早期阶段，可以阻止不可逆的肾脏损伤。

B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) are critical cytokines that promote the differentiation, development and activation of B cells and plasma cells.

B细胞激活因子(BAFF)和增殖诱导配体(APRIL)是促进B细胞和浆细胞分化、发育和激活的关键细胞因子。

Telitacicept, a novel recombinant fusion protein that dual-targets BAFF and APRIL, exhibits considerable therapeutic potential by inhibiting the production of Gd-IgA1 and its autoantibodies.

Telitacicept是一种新型重组融合蛋白，双重靶向BAFF和APRIL，通过抑制Gd-IgA1及其自身抗体的产生，显示出相当大的治疗潜力。

Stage A results of the Phase 3 clinical trial demonstrated that patients in the telitacicept group achieved a 55% reduction in 24-h urinary protein-to-creatinine ratio and stable estimated glomerular filtration rate at Week 39 versus the placebo group, with favorable tolerability and safety.

III期临床试验A阶段结果显示，与安慰剂组相比，telitacicept组患者在第39周时24小时尿蛋白与肌酐比值降低了55%，估算肾小球滤过率保持稳定，并显示出良好的耐受性和安全性。

This review summarizes current progresses in targeting Gd-IgA1-producing cells for the treatment of IgAN, with a focus on therapeutic strategies including BAFF/APRIL inhibitors.

本综述总结了针对产生Gd-IgA1细胞治疗IgA肾病的最新进展，重点介绍了包括BAFF/APRIL抑制剂在内的治疗策略。

Furthermore, it delineates the major challenges and future research directions aimed at optimizing these interventions.

此外，它还概述了旨在优化这些干预措施的主要挑战和未来研究方向。